U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C10H15N3S.2ClH
Molecular Weight 282.233
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TALIPEXOLE DIHYDROCHLORIDE

SMILES

Cl.Cl.NC1=NC2=C(CCN(CC=C)CC2)S1

InChI

InChIKey=DPQAXNSOFFYKDS-UHFFFAOYSA-N
InChI=1S/C10H15N3S.2ClH/c1-2-5-13-6-3-8-9(4-7-13)14-10(11)12-8;;/h2H,1,3-7H2,(H2,11,12);2*1H

HIDE SMILES / InChI

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C10H15N3S
Molecular Weight 209.311
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including http://www.ncbi.nlm.nih.gov/pubmed/8842679

Talipexole is a D2 receptor agonist which was marketed in June 1996 in Japan for the treatment of Parkinson's disease. Clinical trials with talipexole in patients with Parkinson's disease demonstrated statistically significant improvements from baseline for parkinsonian symptoms including akinesia, rigidity, tremor and gait disturbances.

Originator

Curator's Comment: # Boehringer Ingelheim Pharma KG

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
5.8 null [pKi]
7.0 null [pKi]
7.43 null [pKi]
7.09 null [pKi]
7.37 null [pKi]
6.48 null [pKi]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Release and aggregation of cytochrome c and alpha-synuclein are inhibited by the antiparkinsonian drugs, talipexole and pramipexole.
2001 Apr 6
Identification of the dopamine autoreceptor in the guinea-pig retina as D(2) receptor using novel subtype-selective antagonists.
2001 Aug
Postjunctional alpha(2C)-adrenoceptor contractility in human saphenous vein.
2001 Feb 16
Receptor reserve analysis of the human alpha(2C)-adrenoceptor using.
2001 Jan 12
Nonlinear analysis of partial dopamine agonist effects on cAMP in C6 glioma cells.
2001 Jan-Feb
[A-56-year-old woman with parkinsonism, whose mother had Parkinson's disease].
2001 May
Analysis of ligand activation of alpha 2-adrenoceptor subtypes under conditions of equal G alpha protein stoichiometry.
2001 May
Modulation of ligand responses by coupling of alpha(2A)-adrenoceptors to diverse G(alpha)-proteins.
2001 May 1
alpha(2)-adrenoceptor antagonist properties of OPC-28326, a novel selective peripheral vasodilator.
2001 Oct
Influence of sildenafil on central dopamine-mediated behaviour in male rats.
2002 Feb 15
Repeated administration of methamphetamine causes hypersensitivity of D2 receptor in rat ventral tegmental area.
2003 Aug 21
Prolonged drug-induced hypothermia in experimental stroke.
2003 Mar-Apr
Effects of an alpha2-adrenoceptor agonist in nasal mucosa.
2003 Oct
Blood pressure and alpha-vascular reactivity in hypertensive rats treated with amlodipine and dietary Ca.
2004 Apr 5
Immunohistochemical and functional evidence for a noradrenergic regulation in the horse penile deep dorsal vein.
2004 Dec
An update on the dopaminergic treatment of restless legs syndrome and periodic limb movement disorder.
2004 May 1
Practice parameters for the dopaminergic treatment of restless legs syndrome and periodic limb movement disorder.
2004 May 1
Low dose pramipexole is neuroprotective in the MPTP mouse model of Parkinson's disease, and downregulates the dopamine transporter via the D3 receptor.
2004 Oct 11
Drug treatment of Parkinson's disease.
2004 Sep
Antagonistic activity of ascorbic acid (vitamin C) on dopaminergic modulation: apomorphine-induced stereotypic behavior in mice.
2006
Pre-junctional alpha2-adrenoceptors modulation of the nitrergic transmission in the pig urinary bladder neck.
2007
alpha2-adrenoceptor agonists as nasal decongestants.
2007
Mechanism of decongestant activity of alpha 2-adrenoceptor agonists.
2008
Clinical characteristics of restless legs syndrome in end-stage renal failure and idiopathic RLS patients.
2008 Apr 30
Dopamine receptor agonists reverse behavioral abnormalities of alpha-synuclein transgenic mouse, a new model of Parkinson's disease.
2008 Feb 15
Genetic findings in Parkinson's disease and translation into treatment: a leading role for mitochondria?
2008 Mar
Effective control of catatonia in Parkinson's disease by electroconvulsive therapy: a case report.
2009 Feb
Oxidative stress induction of DJ-1 protein in reactive astrocytes scavenges free radicals and reduces cell injury.
2009 Jan-Mar
Pharmacokinetic profile of talipexole in healthy volunteers is not altered when it is co-administered with Madopar (co-beneldopa).
2009 Jun
Oxidative neurodegeneration is prevented by UCP0045037, an allosteric modulator for the reduced form of DJ-1, a wild-type of familial Parkinson's disease-linked PARK7.
2009 Nov 5
The neuroprotective effect of talipexole from paraquat-induced cell death in dopaminergic neuronal cells.
2010 Dec
Effect of bromocriptine on the severity of ovarian hyperstimulation syndrome and outcome in high responders undergoing assisted reproduction.
2010 May
[Dopaminergic neuroprotection and reconstruction of neural network tiara].
2010 Oct
Patents

Patents

Sample Use Guides

Initially 0.2 or 0-4 mg/day, increased by 0.4 mg every week (usual maintenance dosage 1.2 to 3.6 mg/day) Below 0.8 mg/day, once a day; 0.8 to 1.2 mg/day, twice a day; over 1.2 mg/day, 3 times a day
Route of Administration: Oral
In Vitro Use Guide
Talipexole at low concentration (0.1-1 mM) significantly inhibited the accumulation of cytochrome c in the cytosolic fraction of human neuroblastoma SH-SY5Y cells
Substance Class Chemical
Created
by admin
on Wed Jul 05 22:58:42 UTC 2023
Edited
by admin
on Wed Jul 05 22:58:42 UTC 2023
Record UNII
9R6E1D8H1O
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TALIPEXOLE DIHYDROCHLORIDE
MI  
Common Name English
TALIPEXOLE HYDROCHLORIDE
JAN   MART.   WHO-DD  
Common Name English
TALIPEXOLE DIHYDROCHLORIDE [MI]
Common Name English
Talipexole hydrochloride [WHO-DD]
Common Name English
TALIPEXOLE HYDROCHLORIDE [JAN]
Common Name English
TALIPEXOLE HYDROCHLORIDE [MART.]
Common Name English
TALIPEXOLE HCL
Common Name English
Code System Code Type Description
CAS
36085-73-1
Created by admin on Wed Jul 05 22:58:42 UTC 2023 , Edited by admin on Wed Jul 05 22:58:42 UTC 2023
PRIMARY
PUBCHEM
104870
Created by admin on Wed Jul 05 22:58:42 UTC 2023 , Edited by admin on Wed Jul 05 22:58:42 UTC 2023
PRIMARY
SMS_ID
100000090502
Created by admin on Wed Jul 05 22:58:42 UTC 2023 , Edited by admin on Wed Jul 05 22:58:42 UTC 2023
PRIMARY
FDA UNII
9R6E1D8H1O
Created by admin on Wed Jul 05 22:58:42 UTC 2023 , Edited by admin on Wed Jul 05 22:58:42 UTC 2023
PRIMARY
EPA CompTox
DTXSID20189669
Created by admin on Wed Jul 05 22:58:42 UTC 2023 , Edited by admin on Wed Jul 05 22:58:42 UTC 2023
PRIMARY
EVMPD
SUB04670MIG
Created by admin on Wed Jul 05 22:58:42 UTC 2023 , Edited by admin on Wed Jul 05 22:58:42 UTC 2023
PRIMARY
MERCK INDEX
M10441
Created by admin on Wed Jul 05 22:58:42 UTC 2023 , Edited by admin on Wed Jul 05 22:58:42 UTC 2023
PRIMARY Merck Index
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY